Professional Documents
Culture Documents
Latest DPCO 2024
Latest DPCO 2024
Latest DPCO 2024
-33004/99
सी.जी.-डी.एल.-अ.-30032024-253444
xxxGIDHxxx
CG-DL-E-30032024-253444
xxxGIDExxx
असाधारण
EXTRAORDINARY
भाग II—खण्ड 3—उप-खण्ड (ii)
PART II—Section 3—Sub-section (ii)
प्राजधकार से प्रकाजित
PUBLISHED BY AUTHORITY
( )
( )
a b
@ 0.00551% बढाकर
(0.00551%
ऐिीटलोववि
पाउडर फोर इजं ेक्शन 250 4663(अ)
11 1 वाईल 426.40 25-10-23
मिलीग्राि
ऐिीटलोववि
पाउडर फोर इजं ेक्शन 500 4663(अ)
12 1 वाईल 528.45 25-10-23
मिलीग्राि
13 ऐिीटलोववि गोली 800 मिलीग्राि 1 गोली 37.66 1574(अ) 31-03-23
14 ऐिीटलोववि ओइटं िेंट 3% 1 ग्राि 11.67 1574(अ) 31-03-23
vksjy fyD;wbZM 400 4663(अ)
15
fexzk-@5 fefy-
1 fefy- 1.36 25-10-23
16 एडेनोिाइन इजं ेक्शन 3 मिलीग्राि/मि.ली. 1 मि.ली. 92.86 4663(अ) 25-10-23
17 एड्रेनालाईन इजं ेक्शन1मिलीग्राि/मि.ली. 1 मि.ली. 12.23 1574(अ) 31-03-23
vksjy fyD;wbZM 200 1577(अ)
18
fexzk-@5 fefy-
1 fefy- 1.79 31-03-23
19 xksyh 400 fexzk- 1 xksyh 7.04 1577(अ) 31-03-23
च्बेवेबल xksyh 400 4663(अ)
20 1 xksyh 8.13 25-10-23
fexzk-
21 एलोप्यूररनॉल गोली 300 मिलीग्राि 1 गोली 5.63 4663(अ) 25-10-23
22 एलोप्यूररनॉल गोली 100 मिलीग्राि 1 गोली 1.89 1574(अ) 31-03-23
इजं ेक्शन 0.5 1574(अ)
23 अलप्रोस्ट्टैजडल 1 मि.ली. 6106.75 31-03-23
मिलीग्राि/मि.ली.
इंजेटशन 250 4663(अ)
24 एजमकाजसन 1 मम.ली. 54.17 25-10-23
ममलीग्राम /मम.ली.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 3
ममलीग्राम
74 बैसलोफे न गोली 20 मिलीग्राि 1 गोली 16.28 1574(अ) 31-03-23
75 बैसलोफे न गोली 10 मिलीग्राि 1 गोली 11.90 4663(अ) 25-10-23
76 बैसलोफे न गोली 5 मिलीग्राि 1 गोली 6.37 4663(अ) 25-10-23
बेंडामुस्ट्टाइन इजं ेक्शन 100 मिलीग्राि / 1574(अ)
77 1 वाईल 4946.80 31-03-23
हाइड्रोसलोराइड वाईल
78 बेंजोइल पेरोससाइड जेल 2.5 1 ग्राि 3.62 1574(अ) 31-03-23
79 बेंजोइल पेरोससाइड जेल 5 % 1 ग्राि 7.97 1574(अ) 31-03-23
80 बेंजोइल पेरोससाइड जेल 3.5% 1 ग्राम 10.11 1578(अ) 31-03-23
batSD'ku 4 fexzk- 1577(अ)
81
@fefy-
1 fefy- 4.74 31-03-23
82 बेटामेथासोन वैलेरेट क्रीि 0.05% 1 ग्राि 0.67 1574(अ) 31-03-23
83 बेटामेथासोन वैलेरेट क्रीि 0.1% 1 ग्राि 1.04 1574(अ) 31-03-23
84 बाइकलुटामाइड गोली 50 मिलीग्राि 1 गोली 43.30 1574(अ) 31-03-23
85 जबसकॉडल गोली 5 मिलीग्राि 1 गोली 1.17 4663(अ) 25-10-23
86 जबसकॉडल सपोमसटरी 5 मिलीग्राि 1 सपोमसटरी 9.98 4663(अ) 25-10-23
पाउडर फोर इजं ेक्शन 15 1574(अ)
87 ब्लोमाइजसन 1 वाईल 677.41 31-03-23
यमू नट् स
पाउडर फोर इजं ेक्शन 2 4663(अ)
88 बोटेजोजमब 1 वाईल 5260.50 25-10-23
मिलीग्राि
jslfijsVkWjh lksyq'ku 4663(अ)
89 QkWj ;wt bu uscy q kbtj 1 fefy- 11.90 25-10-23
0-5 fexzk-@fefy-
jslfijsVkWjh lksyq'ku 1577(अ)
90 QkWj ;wt bu uscy q kbtj 1 fefy- 13.14 31-03-23
1 fexzk-@fefy-
batSD'ku 0-5% ds lkFk 4663(अ)
91 1 fefy- 7.39 25-10-23
7-5% Xywdkst
92 batSD'ku 0-50% 1 fefy- 4.42 4663(अ) 25-10-23
93 batSD'ku 0-25% 1 fefy- 2.83 4663(अ) 25-10-23
गोली (सब(मलंगिं ल- 0.4 4663(अ)
94 बुप्रेनॉर्फच न 1 गोली 9.43 25-10-23
मिलीग्राि
गोली (मलंगिं ल-सब) 2 4663(अ)
बुप्रेनॉर्फच न (ए)
95 मिलीग्राि + (ए) 0.5 1 गोली 36.98 25-10-23
+नालॉससोन (बी)
मिलीग्राि (बी)
गोली 0.4 )मलंगिं ल-सब) 4663(अ)
बुप्रेनॉर्फच न (ए)
96 मिलीग्राि (ए) + 0.1 1 गोली 11.82 25-10-23
+नालॉससोन (बी)
मिलीग्राि (बी)
ओरल मलमक्वड 20 1574(अ)
97 कै फीन 1 मि.ली. 245.68 31-03-23
मिलीग्राि/मि.ली.
batSD'ku 20 fexzk- 1577(अ)
98
@fefy-
1 fefy- 250.50 31-03-23
yks'ku ¼vkbZih ds 1577(अ)
99
vuqlkj½
1 fefy- 0.95 31-03-23
100 कै जल्ियम फोजलनेट गोली 15 मिलीग्राि 1 गोली 47.54 4663(अ) 25-10-23
101 कै पेजसटाबाइन गोली 500 मिलीग्राि 1 गोली 112.73 4663(अ) 25-10-23
िोडीफाइड ररलीज – गोली 4663(अ)
102 काबाचमेिापाइन 1 गोली 2.40 25-10-23
200 मिलीग्राि
6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
241 इफावरे न्ि गोली 600 मिलीग्राि 1 गोली 70.59 1574(अ) 31-03-23
242 xksyh 200 fexzk- (पी) 1 xksyh 22.54 4663(अ) 25-10-23
र्कैप्िल
ू 200
243 1 कै प्सूल 21.98 2124(अ) 04-05-23
ममलीग्राम
244 एनालाजप्रल गोली 5 मिलीग्राि 1 गोली 3.70 1574(अ) 31-03-23
245 एनालाजप्रल गोली 2.5 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23
batSD'ku 40 fexzk-@0-4
fefy-
246
batSD'ku 60 fexzk-@0-6
0-1 fefy- 111.99 4663(अ) 25-10-23
fefy-
247 एंटेकावीर गोली 1 मिलीग्राि 1 गोली 130.24 4663(अ) 25-10-23
248 एंटेकावीर गोली 0.5 मिलीग्राि 1 गोली 84.44 4663(अ) 25-10-23
249 एररथ्रोपोइटीन इजं ेक्शन 2000 1 मि.ली. 549.58 1574(अ) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 11
आईय/ू मि.ली.
इजं ेक्शन 10000 आईयू 1574(अ)
250 एररथ्रोपोइटीन 1 मि.ली. 1969.11 31-03-23
/मि.ली.
251 एजस्ट्सटालोप्राम गोली 5 मिलीग्राि 1 गोली 5.02 1574(अ) 31-03-23
252 एजस्ट्सटालोप्राम गोली 10 मिलीग्राि 1 गोली 9.00 1574(अ) 31-03-23
253 एजस्ट्सटालोप्राम गोली 20 मिलीग्राि 1 गोली 14.36 1574(अ) 31-03-23
batSD'ku 10 fexzk- 1577(अ)
254
@fefy-
1 fefy- 26.38 31-03-23
255 एथेमब्युटोल गोली 600मिलीग्राि 1 गोली 4.08 1574(अ) 31-03-23
256 एथेमब्युटोल गोली 800 मिलीग्राि 1 गोली 4.96 4663(अ) 25-10-23
257 एथेमब्युटोल गोली 400 मिलीग्राि 1 गोली 2.61 1574(अ) 31-03-23
258 xksyh 200 fexzk- 1 xksyh 1.14 1577(अ) 31-03-23
गोली 0.03 मिलीग्राि (ए)
एजथजनलएस्ट्राजडयोल (ए)
259 + गोली 0.15 मिलीग्राि 1 गोली 3.17 1574(अ) 31-03-23
+ लेवोनोगेस्ट्रेल (बी)
(बी)
260 एजथओनामाइड गोली 250 मिलीग्राि 1 गोली 14.81 1574(अ) 31-03-23
261 एटोपोसाइड कै प्सूल 50 मिलीग्राि 1 कै प्सूल 56.63 1574(अ) 31-03-23
इजं ेक्शन 20 1574(अ)
262 एटोपोसाइड 1 मि.ली. 34.51 31-03-23
मिलीग्राि/मि.ली.
263 दफल्ग्राजस्ट्टम इजं ेक्शन 300 एिसीजी 1 वाइल 1159.97 1574(अ) 31-03-23
264 फ्लुकोनाजोल गोली 400 मिलीग्राि 1 गोली 29.75 4663(अ) 25-10-23
265 फ्लूकोनाजोल गोली 200 मिलीग्राि 1 गोली 17.46 4663(अ) 25-10-23
266 फ्लूकोनाजोल गोली 100 मिलीग्राि 1 गोली 7.62 1574(अ) 31-03-23
267 फ्लुकोनाजोल गोली 150 मिलीग्राि 1 गोली 12.06 1574(अ) 31-03-23
268 फ्लुकोनाजोल गोली 50 मिलीग्राि 1 गोली 9.68 4663(अ) 25-10-23
269 dSIlwy 200 fexzk- 1 dSIlwy 40.11 4663(अ) 25-10-23
270 dSIlwy 150 fexzk- 1 dSIlwy 19.22 4663(अ) 25-10-23
batSD'ku 200 fexzk-@ izfr 100 1577(अ)
271
100 fefy- fefy- वाईल 92.33 31-03-23
1000 fexzk-
341 इमैरटजनब गोली 100 मिलीग्राि 1 गोली 69.75 1574(अ) 31-03-23
342 इमैरटजनब गोली 400 मिलीग्राि 1 गोली 199.62 1574(अ) 31-03-23
343 dSIlwy 100 fexzk- 1 dSIlwy 73.48 1577(अ) 31-03-23
batSD'ku 40 4663(अ)
344
vkbZ;w@fefy-
1 fefy- 16.99 25-10-23
इंजेटशन 100 4663(अ)
345 इं सुजलन ललार्िचन 1 fefy- 203.46 25-10-23
आईयू / मम.ली.
इं सुजलन इं टरमीजडएट 4663(अ)
346 इजं ेक्शन 40 आई/मि.ली. 1 मि.ली. 16.99 25-10-23
एकसटंग (एनपीएर्)
batSD'ku 300 fexzk- 4663(अ)
347
vk;ksfMu@fefy-
1 fefy- 16.90 25-10-23
इंजेटशन 140 to
350 ममलीग्राम
348 आयोहेससोल 1 मम.ली. 14.24 4663(अ) 25-10-23
आयोडडन.ली.मम/
(350ममलीग्राम)
इंजेटशन हे तु
इररनोटेकन
349 िॉेयश
ू न 20 1 मम.ली. 964.89 1579(अ) 31-03-23
एर्सीएलररहाइड्रेट
ममलीग्राम/मम.ली.
इजं ेक्शन 20 4663(अ)
350 आयरन सुक्रोि 1 मि.ली. 57.41 25-10-23
मिलीग्राि/मि.ली.
351 आइसोफ्लुरेन मलक़िंड फोर इनहेलेशन 1 मि.ली. 9.65 1574(अ) 31-03-23
352 आइसोजनयाजजड गोली 300 मिलीग्राि 1 गोली 1.29 2540(अ) 08-06-23
353 आइसोजनयाजजड गोली 100 मिलीग्राि 1 गोली 0.65 2540(अ) 08-06-23
354 आइसोसॉरबाइड जडजनरेट गोली 5 मिलीग्राि 1 गोली 0.82 4663(अ) 25-10-23
355 आइसोसॉरबाइड जडजनरेट गोली 10मिलीग्राि 1 गोली 0.81 4663(अ) 25-10-23
356 इस्ट्पघुला ग्रेनल
िं ेस/ हस्कपाउडर / 1 ग्राि 0.94 1574(अ) 31-03-23
ओरल मलमक्वड 10
357 इराकोनािोल मिलीग्राि / मि.ली. 1 मि.ली. 4.94 1574(अ) 31-03-23
र्कैप्िल
ू 100
358 इराकोनािोल 1 र्कैप्िल
ू 16.67 1579(अ) 31-03-23
ममलीग्राम
र्कैप्िल
ू 200
359 इराकोनािोल 1 र्कैप्िल
ू 22.12 1579(अ) 31-03-23
ममलीग्राम
360 ykblsal ds :i esa 1 vkbZ;wMh 281.02 4663(अ) 25-10-23
361 आइवरमेजसटन गोली 6 ममलीग्राम 1 गोली 21.58 1578(अ) 31-03-23
362 आइवरमेजसटन गोली 12 ममलीग्राम 1 गोली 37.37 1578(अ) 31-03-23
लाइिेंि र्के अनि
ु ाि
िापनीि इं सेफेलाइरटस
363 (4 एमिीजी िे 6 1 वाइल 677.17 2124(अ) 04-05-23
वैससीन
एमिीजी)
िापनीि इं सेफेलाइरटस लाइिेंि र्के अनि
ु ाि
364 1 वाइल 518.66 2124(अ) 04-05-23
वैससीन (3 एमिीजी तर्क)
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 15
इजं ेक्शन 50
365 के टामाइन 1 मि.ली. 12.12 1574(अ) 31-03-23
मिलीग्राि/मि.ली.
366 लेबेटालोल इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 49.98 1574(अ) 31-03-23
गोली 100
367 लेबेटालोल 1 गोली 15.16 4663(अ) 25-10-23
ममलीग्राम
ओरल मलमक्वड 10 ग्राि
368 लैसटु लोि 1 मि.ली. 1.23 1574(अ) 31-03-23
/15मि.ली.
369 लैमीवुडीन गोली 100 मिलीग्राि 1 गोली 10.40 1574(अ) 31-03-23
370 लैमीवुडीन गोली 150 मिलीग्राि 1 गोली 10.86 1574(अ) 31-03-23
पाउडर फोर इजं ेक्शन 5000
371 एल- ऐस्ट्पैरिाइनेस 1 वाईल 1034.88 4663(अ) 25-10-23
के यू
पाउडर फोर इजं ेक्शन
372 एल- ऐस्ट्पैरिाइनेस 1 वाईल 1707.74 4663(अ) 25-10-23
10000 के यू
373 लैटानोप्रोस्ट्ट ड्रोप 0.005% 1 मि.ली. 232.58 2542(अ) 08-06-23
374 लेजनलेडोमाइड कै प्सूल 5 मिलीग्राि 1 कै प्सूल 67.25 1574(अ) 31-03-23
375 लेजनलेडोमाइड कै प्सूल 25 मिलीग्राि 1 कै प्सूल 292.28 4663(अ) 25-10-23
376 लेरोजोल गोली 2.5 मिलीग्राि 1 गोली 29.32 4663(अ) 25-10-23
पाउडर फोर इजं ेक्शन 22.5
377 ल्यूप्रोलाइड एसीटेट 1 वाईल 17081.50 4663(अ) 25-10-23
मिलीग्राि
पाउडर फोर इजं ेक्शन
378 ल्यूप्रोलाइड एसीटेट 1 वाईल 9294.48 4663(अ) 25-10-23
11.25 मिलीग्राि
पाउडर फोर इजं ेक्शन 3.75
379 ल्यूप्रोलाइड एसीटे ट 1 वाईल 3112.67 1574(अ) 31-03-23
मिलीग्राि
380 लेवेरटरासेटम गोली 250 मिलीग्राि 1 गोली 6.30 1574(अ) 31-03-23
381 लेवेरटरासेटम गोली 500 मिलीग्राि 1 गोली 12.98 1574(अ) 31-03-23
िोडीफाइड ररलीज गोली
382 लेवेरटरासेटम 1 गोली 18.30 4663(अ) 25-10-23
750 मिलीग्राि
383 लेवेरटरासेटम गोली 750 मिलीग्राि 1 गोली 19.34 1574(अ) 31-03-23
ओरल मलमक्वड 100
384 लेवेरटरासेटम 1 मि.ली. 3.97 4663(अ) 25-10-23
मिलीग्राि/मि.ली. (पी)
इजं ेक्शन 100 मिलीग्राि/
385 लेवेरटरासेटम 1 मि.ली. 23.02 4663(अ) 25-10-23
मि.ली.
िोडीफाईड ररलीज –गोली
लेवोडोपा (ए) +
386 200 मिलीग्राि (ए) + 1 गोली 4.73 1574(अ) 31-03-23
कार्बचडोपा (बी)
50 मिलीग्राि (बी)
गोली 100 ममलीग्राम
लेवोडोपा (ए) +
387 (ए) + 25 ममलीग्राम 1 गोली 2.58 4663(अ) 25-10-23
कार्बचडोपा (बी)
(बी)
गोली 100 ममलीग्राम
लेवोडोपा (ए) +
388 (ए) + 10 ममलीग्राम 1 गोली 1.76 1574(अ) 31-03-23
कार्बचडोपा (बी)
(बी)
लेवोडोपा (ए) + गोली 250 मिलीग्राि (ए)
389 1 गोली 4.42 4663(अ) 25-10-23
कार्बचडोपा (बी) +25 मिलीग्राि (बी)
िोडीफाइड ररलीज –गोली
लेवोडोपा (ए) +
390 100 मिलीग्राि (ए) + 25 1 गोली 2.79 1574(अ) 31-03-23
कार्बचडोपा (बी)
मिलीग्राि (बी)
16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
जनकोटीन (जनकोटीन
480 लॉजेंग 4 ममलीग्राम 1 लॉजेंग 9.75 1579(अ) 31-03-23
ररप्लेसमेंट थेरेपी के जलए)
481 जनफे जडजपन गोली 10 मिलीग्राि 1 गोली 1.54 4663(अ) 25-10-23
482 dSIlwy 10 fexzk- 1 dSIlwy 0.95 1577(अ) 31-03-23
483 नाइट्रोफ्यिू न्टाइन गोली 100 मिलीग्राि 1 गोली 8.11 4663(अ) 25-10-23
484 नन टोइन dSIlwy 100 fexzk- 1 dSIlwy 8.64 1577(अ) 31-03-23
vksjy fyD;wbZM 25
485 टोइन fexzk-@5 fefy-
1 fefy- 0.89 4663(अ) 25-10-23
इजं ेक्शन 2 मिलीग्राि/
486 नॉिएड्रेनालाईन 1 मि.ली. 20.17 1574(अ) 31-03-23
मि.ली.
487 नोिे धिस्टिोन गोली 5 मिलीग्राि 1 गोली 5.39 1574(अ) 31-03-23
488 ओमेप्राज़ोल कै प्सूल 20 मिलीग्राि 1 कै प्सूल 2.87 1574(अ) 31-03-23
489 xksyh 20 fexzk- 1 xksyh 4.34 4663(अ) 25-10-23
490 dSIlwy 10 fexzk- 1 dSIlwy 2.41 1577(अ) 31-03-23
vksjy fyD;wbZM ds fy,
491
ikmMj 20 fexzk-
1 xzke 1.51 1577(अ) 31-03-23
492 dSIlwy 40 fexzk- 1 dSIlwy 8.45 1577(अ) 31-03-23
493 ओंडान्िेट्रॉन गोली 4 मिलीग्राि 1 गोली 5.14 4663(अ) 25-10-23
ओरल मलमक्वड 2
494 ओंडान्िेट्रॉन 1 मि.ली. 1.26 4663(अ) 25-10-23
मिलीग्राि/5 मि.ली. (पी)
495 ओंडान्िेट्रॉन इजं ेक्शन 2 मिलीग्राि/मि.ली. 1 मि.ली. 5.96 1574(अ) 31-03-23
496 ओंडान्िेट्रॉन गोली 8 मिलीग्राि 1 गोली 9.06 4663(अ) 25-10-23
497 ykblsal ds :i esa 1 fefy- 0.15 4663(अ) 25-10-23
ऑरमेलोजससफे न
498 गोली 30 जमलीग्राम 1 गोली 8.44 1579(अ) 31-03-23
(सेंटक्रोमन)
इजं ेक्शन 5
499 ऑक्टिक्प्लक्प्टन मिलीग्राि/मि.ली. in 10 1 वाईल 2233.95 4663(अ) 25-10-23
मि.ली. वाईल
500 ऑटिीटोमिन इजं ेक्शन 5 आईय/ू मि.ली. 1 मि.ली. 17.84 4663(अ) 25-10-23
batSD'ku 10
501 1 fefy- 39.87 1577(अ) 31-03-23
vkbZ;w@fefy-
batSD'ku 30 fexzk-@5
502 fefy-batSD'ku 100 1 fefy- 215.44 1577(अ) 31-03-23
fexzk-@16-7 fefy-
503 पैंटोप्राज़ोल इजं ेक्शन 40 मिलीग्राि 1 वाईल 50.45 1574(अ) 31-03-23
504 पेिामिटामोल गोली 650 मिलीग्राि 1 गोली 2.01 4663(अ) 25-10-23
ओरल मलमक्वड 125
505 पेिामिटामोल 1 मि.ली. 0.37 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
ओरल मलमक्वड 250
506 पेिामिटामोल 1 मि.ली. 0.67 1574(अ) 31-03-23
मिलीग्राि/5 मि.ली. (पी)
ओरल मलमक्वड 120
507 पेिामिटामोल 1 मि.ली. 0.61 4663(अ) 25-10-23
मिलीग्राि/5 मि.ली. (पी)
20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
621 िम
ु ाट्रट्रप्टान गोली 25 मिलीग्राि 1 गोली 32.50 2540(अ) 08-06-23
622 िम
ु ाट्रट्रप्टान गोली 50 मिलीग्राि 1 गोली 55.68 2540(अ) 08-06-23
623 टै क्रोमलमि कै प्सल
ू 0.5 मिलीग्राि 1 कै प्सल
ू 20.66 1574(अ) 31-03-23
624 टै क्रोमलमि कै प्सूल 1 मिलीग्राि 1 कै प्सूल 40.62 1574(अ) 31-03-23
625 टै क्रोमलमि कै प्सूल 2 मिलीग्राि 1 कै प्सूल 84.34 4663(अ) 25-10-23
626 टै क्रोमलमि गोली 1 मिलीग्राि 1 गोली 39.98 4886(अ) 10-11-23
627 टै क्रोमलमि गोली 2 मिलीग्राि 1 गोली 77.69 4886(अ) 10-11-23
628 टै क्रोमलमि गोली 0.5 मिलीग्राि 1 गोली 20.97 4886(अ) 10-11-23
629 टामोटिीफेन गोली 20 मिलीग्राि 1 गोली 2.95 4663(अ) 25-10-23
630 टामोटिीफेन गोली 10 मिलीग्राि 1 गोली 2.21 4663(अ) 25-10-23
631 टे क्ेमिटि न गोली 20 मिलीग्राि 1 गोली 3.88 4663(अ) 25-10-23
632 टे क्ेमिटि न गोली 40 मिलीग्राि 1 गोली 6.76 1574(अ) 31-03-23
633 टे क्ेमिटि न गोली 80 मिलीग्राि 1 गोली 10.40 1574(अ) 31-03-23
634 टे मोज़ोलोमाइड कै प्सूल 20 मिलीग्राि 1 कै प्सूल 441.33 1574(अ) 31-03-23
635 टे मोज़ोलोमाइड कै प्सल
ू 250 मिलीग्राि 1 कै प्सल
ू 4304.01 1574(अ) 31-03-23
636 टे मोज़ोलोमाइड कै प्सूल 100 मिलीग्राि 1 कै प्सूल 1508.70 1574(अ) 31-03-23
637 टे मोज़ोलोमाइड गोली 20 मिलीग्राि 1 गोली 336.65 4886(अ) 10-11-23
638 टे मोज़ोलोमाइड गोली 250 मिलीग्राि 1 गोली 3758.15 4886(अ) 10-11-23
इजं ेक्शन 40 मिलीग्राि /
639 टे नेटटे प्लेि 1 वाईल 50389.69 4663(अ) 25-10-23
वाईल
इजं ेक्शन 30 मिलीग्राि /
640 टे नेटटे प्लेि 1 वाईल 36910.02 4663(अ) 25-10-23
वाईल
641 टे नेमलक्ललक्प्टन गोली 20 ममलीग्राम 1 गोली 11.09 4663(अ) 25-10-23
टे नोफोववि
642 अलाफेनामाइड गोली 25 मिलीग्राि 1 गोली 48.87 1574(अ) 31-03-23
फ्यम
ू िे ट (टीएएफ)
टे नोफोववि
डडिोप्रोटिील गोली 300 मिलीग्राि (ए)
643 1 गोली 45.58 4663(अ) 25-10-23
फ्यम
ू िे ट (ए) + + 300 मिलीग्राि (बी)
लैममवड
ु ाइन (बी)
टे नोफोववि
डडिोप्रॉक्टिल गोली 300 मिलीग्राि (ए)
644 फ्यम
ू िे ट) + + 300 मिलीग्राि (बी) + 1 गोली 102.85 4663(अ) 25-10-23
लैममवड
ु ाइन (बी) + 600 मिलीग्राि (सी)
ए़िावविें ज़ (िी)
टे नोफोववि
डडिप्रॉक्टिल
645 गोली 300 मिलीग्राि 1 गोली 45.84 4663(अ) 25-10-23
फ्यम
ू िे ट (टी डी
एफ)*
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 25
लैममवडु डन +
डोेयट
ू े ग्रेववि
698 xksyh 300 fexzk- 1 xksyh 13.59 938(अ) 28-02-24
batSD'ku ds fy,
699 ikmMj 12 yk[k 1 वाईल 19.81 938(अ) 28-02-24
;wfuV
batSD'ku ds fy,
700 ikmMj 6 yk[k 1 वाईल 11.69 938(अ) 28-02-24
;wfuV
batSD'ku 50
701 1 fefy- 20.96 938(अ) 28-02-24
,elhth@fefy-
702 dSIlwy 5 fexzk- 1 dSIlwy 5.04 938(अ) 28-02-24
batSD'ku 20 fexzk-
703 1 fefy- 11.24 938(अ) 28-02-24
@fefy-
704 dSIlwy 40 fexzk- 1 dSIlwy 5.67 938(अ) 28-02-24
batSD'ku ds fy,
705 1 वाईल 188.65 938(अ) 28-02-24
ikmMj 500 fexzk-
ykbvksfQykftM 1 वाईल
706 ikWyhosysaV ऐज ओफ 10 665.26 938(अ) 28-02-24
लाइिेंि मम.ली.
lksyqcy@fyD;wbM 1 वाईल
707 ikWyhosysaV ऐज ओफ 10 428.67 938(अ) 28-02-24
लाइिेंि मम.ली.
708 xksyh 2 fexzk- 1 xksyh 31.16 938(अ) 28-02-24
709 xksyh 5 fexzk- 1 xksyh 77.21 938(अ) 28-02-24
710 xksyh 2 fexzk- 1 xksyh 91.34 938(अ) 28-02-24
711 xksyh 5 fexzk- 1 xksyh 86.04 938(अ) 28-02-24
batSD'ku 1 fexzk- 1 fefy-
712
@fefy- 30.54 938(अ) 28-02-24
batSD'ku 250 fexzk-@5 1 fefy-
713
fefy- 2.04 938(अ) 28-02-24
कंनवेंसनल / एफिवेिट ें 1 xksyh
/ डडस्पमििबल /
714 एंटरिर्क लेवपत 0.67 938(अ) 28-02-24
गोमलयााँ 325
ममलीग्राम
bugsys”ku ¼,eMhvkbZ½ 1 ehVj Mkst
715
100 ,elhth@Mkst 1.41 938(अ) 28-02-24
bugsys”ku ¼,eMhvkbZ½ 1 ehVj Mkst
716
200 ,elhth@Mkst 2.03 938(अ) 28-02-24
bugsys”ku ¼MhihvkbZ½ 1 Mkst
717
200 ,elhth@Mkst 3.33 938(अ) 28-02-24
usty Lizs 100 1 Mkst
718
,elhth@Mkst 0.81 938(अ) 28-02-24
bugsys”ku ¼,eMhvkbZ½ 1 ehVj Mkst
719 100 ,elhth ¼,½ $ 6 2.12 938(अ) 28-02-24
,elhth ¼ch½
28 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
-
(
0.00551% )
11(3)
(5)
a b िे
0.00551
(5)
यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध
में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और
इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 29
माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत
अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।
(4)
(ञ)
(1) u
II I
II III
II IV
TABLE
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Ceiling price Existing S.O., No. & Date
(wef 1.4.2024
Sl. Dosage form and
Medicines Unit with WPI @
No. strength
0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) (6a) (6b)
1 6-Mercaptopurine Tablet 50mg 1 Tablet 5.26 4663(E) 25-10-23
2 Abacavir Tablet 300 mg 1 Tablet 48.59 1574(E) 31-03-23
Abacavir (A) + Lamivudine Tablet 600mg (A) 4663(E) 25-10-23
3 1 Tablet 72.32
(B) +300mg (B)
4 Acetazolamide Tablet 250mg 1 Tablet 4.06 4663(E) 25-10-23
5 Acetazolamide Capsule 250mg 1 Capsule 5.05 4663(E) 25-10-23
Enteric coated 4663(E) 25-10-23
6 Acetylsalicylic acid 1 Tablet 0.35
Tablet 75 mg
Conventional/Effer 4663(E) 25-10-23
vescent/Dispersible/
7 Acetylsalicylic acid 1 Tablet 0.71
Enteric coated
Tablets 150 mg
Powder for 4663(E) 25-10-23
8 Actinomycin D 1 Vial 331.03
Injection 0.5mg
9 Acyclovir Tablet 400mg 1 Tablet 13.66 4663(E) 25-10-23
10 Acyclovir Tablet 200mg 1 Tablet 7.61 1574(E) 31-03-23
Powder for 4663(E) 25-10-23
11 Acyclovir 1 Vial 426.40
Injection 250 mg
Powder for 4663(E) 25-10-23
12 Acyclovir 1 Vial 528.45
Injection 500 mg
13 Acyclovir Tablet 800mg 1 Tablet 37.66 1574(E) 31-03-23
14 Acyclovir Ointment 3% 1 GM 11.67 1574(E) 31-03-23
Oral liquid 4663(E) 25-10-23
15 Acyclovir 1 ML 1.36
400mg/5mL (p)
16 Adenosine Injection 3mg/mL 1 ML 92.86 4663(E) 25-10-23
17 Adrenaline Injection1mg/mL 1 ML 12.23 1574(E) 31-03-23
Oral liquid 1577(E) 31-03-23
18 Albendazole 1 ML 1.79
200mg/5mL(p)
19 Albendazole Tablet 400mg 1 Tablet 7.04 1577(E) 31-03-23
Chewable Tablet 4663(E) 25-10-23
20 Albendazole 1 Tablet 8.13
400mg
21 Allopurinol Tablet 300mg 1 Tablet 5.63 4663(E) 25-10-23
22 Allopurinol Tablet 100mg 1 Tablet 1.89 1574(E) 31-03-23
23 Alprostadil Injection 0.5mg/mL 1 ML 6106.75 1574(E) 31-03-23
Injection 4663(E) 25-10-23
24 Amikacin 1 ML 54.17
250mg/mL
25 Amiodarone Tablet 200mg 1 Tablet 11.51 1574(E) 31-03-23
26 Amiodarone Tablet 100mg 1 Tablet 6.14 1574(E) 31-03-23
27 Amiodarone Injection 50mg/mL 1 ML 21.13 1574(E) 31-03-23
28 Amitriptyline Tablet 50mg 1 Tablet 5.99 4663(E) 25-10-23
29 Amitriptyline Tablet 75mg 1 Tablet 5.45 4663(E) 25-10-23
30 Amitriptyline Tablet 25mg 1 Tablet 2.49 4663(E) 25-10-23
31 Amitriptyline Tablet 10mg 1 Tablet 2.39 4663(E) 25-10-23
32 Amlodipine Tablet 2.5mg 1 Tablet 1.79 1574(E) 31-03-23
33 Amlodipine Tablet 5mg 1 Tablet 2.50 1574(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 31
34 Amlodipine Tablet 10mg 1 Tablet 5.45 4663(E) 25-10-23
35 Amoxicillin Capsule 250mg 1 Capsule 2.44 1574(E) 31-03-23
36 Amoxicillin Capsule 500mg 1 Capsule 7.36 4663(E) 25-10-23
Oral liquid 250 4663(E) 25-10-23
37 Amoxicillin 1 ML 1.56
mg/5 mL (p)
Powder for 1578(E) 31-03-23
38 Amoxicillin 1 Vial 24.79
Injection 250 mg
Powder for 4663(E) 25-10-23
39 Amoxicillin 1 Vial 54.65
Injection 500 mg
Oral liquid 125 1579(E) 31-03-23
40 Amoxicillin 1 ML 1.02
mg/5 mL (p)
Powder for 4663(E) 25-10-23
Amoxicillin (A) + Clavulanic
41 Injection 1 g (A) 1 Vial 140.66
acid (B)
+200mg (B)
Powder for 4663(E) 25-10-23
Amoxicillin (A) + Clavulanic
42 Injection 500mg 1 Vial 101.35
acid (B)
(A) + 100mg (B)
Dry Syrup 125mg 1574(E) 31-03-23
Amoxicillin (A) + Clavulanic
43 (A) + 31.25 1 ML 2.05
acid (B)
(B)/5mL(p)
Amoxicillin (A) +Clavulanic Tablet 500 mg (A) 4663(E) 25-10-23
44 1 Tablet 18.30
acid (B) + 125 mg (B)
Oral liquid 200 mg 4663(E) 25-10-23
Amoxicillin (A) +Clavulanic
45 (A) + 28.5mg(B)/5 1 ML 2.02
acid (B)
mL(p)
Amphotericin 1577(E) 31-03-23
46 Amphotericin B B(conventional) - 1 Vial 227.40
Injection 50mg/vial
Powder for 1574(E) 31-03-23
47 Ampicillin 1 Vial 14.25
Injection 500 mg
Artemether (A) + Tablet 40 mg (A) + 1574(E) 31-03-23
48 1 Tablet 18.04
Lumefantrine (B) 240 mg (B)
Tablet 4663(E) 25-10-23
Artemether (A)
49 80mg(A)+480mg(B 1 Tablet 25.51
+Lumefantrine(B)
)
Artemether (A) +Lumefantrine Tablet 20 mg (A) + 4663(E) 25-10-23
50 1 Tablet 12.65
(B) 120 mg (B)
Powder for 4663(E) 25-10-23
51 Artesunate 1 Vial 244.73
Injection 60 mg
Powder for 4663(E) 25-10-23
52 Artesunate 1 Vial 454.44
Injection 120mg
Combi pack (A+B) 4663(E) 25-10-23
Artesunate (A) + Sulphadoxine 1 Tablet 50mg (A) 1 Combi
53 22.55
-Pyrimethamine (B) + 1Tablet (500mg + Pack
25mg) (B)
54 Ascorbic acid (Vitamin C) Tablet 100mg 1 Tablet 0.24 4663(E) 25-10-23
55 Ascorbic acid (Vitamin C) Tablet 500mg 1 Tablet 1.48 1577(E) 31-03-23
Tablet 300mg(A) + 1574(E) 31-03-23
56 Atazanavir (A) +Ritonavir(B) 1 Tablet 99.83
Tablet 100mg(B)
57 Atorvastatin Tablet 40mg 1 Tablet 19.30 4663(E) 25-10-23
58 Atorvastatin Tablet 20mg 1 Tablet 12.56 4663(E) 25-10-23
59 Atorvastatin Tablet 10mg 1 Tablet 4.94 1574(E) 31-03-23
60 Atorvastatin Tablet 80mg 1 Tablet 40.58 4663(E) 25-10-23
61 Atracurium Injection 10 mg/ml 1 ML 16.98 4663(E) 25-10-23
62 Atropine Drops 1% 1 ML 3.94 4663(E) 25-10-23
63 Atropine Ointment 1% 1 GM 4.71 4663(E) 25-10-23
32 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
(MDI/DPI)
100mcg/dose
Respirator Solution 1574(E) 31-03-23
599 Salbutamol (Solution for 1 ML 0.68
Nebulizer 5mg/mL)
Ointment 3-6% 4663(E) 25-10-23
600 Salicylic acid 1 GM 2.02
(6%)
601 Salicylicacid Ointment 3% 1 GM 2.06 1579(E) 31-03-23
Liquid for 4663(E) 25-10-23
602 Sevoflurane 1 ML 31.17
inhalation
Injection (as per IP) 4663(E) 25-10-23
603 Sodium bicarbonate 1 ML 1.35
- 8.4%
Injection (as per IP) 4663(E) 25-10-23
604 Sodium bicarbonate 1 ML 1.01
- 7.5%
605 Sodium Valproate Tablet 300mg 1 Tablet 4.46 1574(E) 31-03-23
Oral liquid 1574(E) 31-03-23
606 Sodium Valproate 1 ML 0.65
200mg/5mL(p)
607 Sodium Valproate Tablet 200mg 1 Tablet 3.59 4663(E) 25-10-23
Modified Release – 1574(E) 31-03-23
608 Sodium Valproate 1 Tablet 9.28
Tablet 500mg
609 Sodium Valproate Tablet 500mg 1 Tablet 8.12 4663(E) 25-10-23
Modified Release – 4663(E) 25-10-23
610 Sodium Valproate 1 Tablet 6.10
Tablet 300mg
Injection 4663(E) 25-10-23
611 Sodium Valproate 1 ML 6.75
100mg/mL
612 Sofosbuvir Tablet 400mg 1 Tablet 525.12 4663(E) 25-10-23
Powder for 4663(E) 25-10-23
613 Somatostatin 1 Vial 1359.00
Injection 3mg
614 Spironolactone Tablet 50mg 1 Tablet 4.37 1574(E) 31-03-23
615 Spironolactone Tablet 25mg 1 Tablet 2.19 4663(E) 25-10-23
Injection 1574(E) 31-03-23
616 Streptokinase 1 Vial 1877.33
15,00,000IU
Powder for 1574(E) 31-03-23
617 Streptomycin 1 Vial 10.10
Injection 750 mg
Powder for 1574(E) 31-03-23
618 Streptomycin 1 Vial 10.86
Injection 1000mg
619 Succinylcholine Injection 50mg/mL 1 ML 5.21 2540(E) 08-06-23
620 Sulfasalazine Tablet 500 mg 1 Tablet 4.72 1574(E) 31-03-23
621 Sumatriptan Tablet 25mg 1 Tablet 32.50 2540(E) 08-06-23
622 Sumatriptan Tablet 50mg 1 Tablet 55.68 2540(E) 08-06-23
623 Tacrolimus Capsule 0.5mg 1 Capusle 20.66 1574(E) 31-03-23
624 Tacrolimus Capsule 1mg 1 Capusle 40.62 1574(E) 31-03-23
625 Tacrolimus Capsule 2mg 1 Capusle 84.34 4663(E) 25-10-23
626 Tacrolimus Tablet 1mg 1 Tablet 39.98 4886(E) 10-11-23
627 Tacrolimus Tablet 2mg 1 Tablet 77.69 4886(E) 10-11-23
628 Tacrolimus Tablet 0.5mg 1 Tablet 20.97 4886(E) 10-11-23
629 Tamoxifen Tablet 20mg 1 Tablet 2.95 4663(E) 25-10-23
630 Tamoxifen Tablet 10mg 1 Tablet 2.21 4663(E) 25-10-23
631 Telmisartan Tablet 20mg 1 Tablet 3.88 4663(E) 25-10-23
632 Telmisartan Tablet 40mg 1 Tablet 6.76 1574(E) 31-03-23
633 Telmisartan Tablet 80mg 1 Tablet 10.40 1574(E) 31-03-23
634 Temozolomide Capsule 20 mg 1 Capsule 441.33 1574(E) 31-03-23
635 Temozolomide Capsule 250mg 1 Capsule 4304.01 1574(E) 31-03-23
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 47
636 Temozolomide Capsule 100mg 1 Capsule 1508.70 1574(E) 31-03-23
637 Temozolomide Tablet 20 mg 1 Tablet 336.65 4886(E) 10-11-23
638 Temozolomide Tablet 250 mg 1 Tablet 3758.15 4886(E) 10-11-23
639 Tenecteplase Injection 40mg/vial 1 Vial 50389.69 4663(E) 25-10-23
640 Tenecteplase Injection 30mg/vial 1 Vial 36910.02 4663(E) 25-10-23
641 Teneligliptin Tablet 20mg 1 Tablet 11.09 4663(E) 25-10-23
Tenofovir Alafenamide 1574(E) 31-03-23
642 Tablet 25mg 1 Tablet 48.87
Fumarate (TAF)
Tenofovir Disproxil Fumarate Tablet 300mg (A) + 4663(E) 25-10-23
643 1 Tablet 45.58
(A) + Lamivudine (B) 300mg(B)
Tenofovir Disproxil Fumarate Tablet 300mg(A)+ 4663(E) 25-10-23
644 (A) +Lamivudine (B) + 300mg (B) + 1 Tablet 102.85
Efavirenz(C) 600mg(C)
Tenofovir Disproxil Fumarate 4663(E) 25-10-23
645 Tablet 300mg 1 Tablet 45.84
(TDF)*
646 Terbinafine Cream 1% 1 GM 5.26 4663(E) 25-10-23
647 Tetanus toxoid As licensed (5ml) 1 Vial 25.53 1577(E) 31-03-23
1 Vial 4663(E) 25-10-23
648 Tetanus toxoid As licensed (0.5ml) 12.47
(0.5ML)
649 Thalidomide Capsule 50 mg 1 Capsule 31.16 4663(E) 25-10-23
650 Thalidomide Capsule 100mg 1 Capsule 62.01 1574(E) 31-03-23
651 Thiamine Tablet 100 mg 1 Tablet 4.46 1574(E) 31-03-23
Injection 100 1574(E) 31-03-23
652 Thiamine 1 ML 22.59
mg/mL
Powder for 2540(E) 08-06-23
653 Thiopentone 1 Vial 55.32
injection 1g
Powder for 2540(E) 08-06-23
654 Thiopentone 1 Vial 45.69
injection 0.5g
655 Timolol Drops 0.5 % 1 ML 13.40 4663(E) 25-10-23
Inhalation (MDI) 9 1574(E) 31-03-23
656 Tiotropium 1 MD 2.78
mcg/dose
Inhalation (DPI) 4663(E) 25-10-23
657 Tiotropium 1 DP 10.71
18mcg/dose
Injection 50mg/mL 1574(E) 31-03-23
658 Tramadol 1 ML 11.78
(upto 2ml pack)
659 Tramadol Capsule 50mg 1 Capsule 4.82 1577(E) 31-03-23
660 Tramadol Capsule 100mg 1 Capsule 9.04 4663(E) 25-10-23
661 Tramadol Tablet 50mg 1 Tablet 9.70 4886(E) 10-11-23
662 Tramadol Tablet 100mg 1 Tablet 24.48 4886(E) 10-11-23
Injection 100 1574(E) 31-03-23
663 Tranexamic acid 1 ML 13.71
mg/mL
664 Tranexamic acid Tablet 500 mg 1 Tablet 18.54 1574(E) 31-03-23
Injection 4663(E) 25-10-23
665 Trastuzumab 1 Vial 54725.21
440mg/50mL
666 Trihexyphenidyl Tablet 2mg 1 Tablet 1.37 4663(E) 25-10-23
667 Tropicamide Eye drop 1 % 1 ML 9.43 4663(E) 25-10-23
668 Valganciclovir Tablet 450 mg 1 Tablet 400.73 1574(E) 31-03-23
Powder for 4663(E) 25-10-23
669 Vancomycin 1 Vial 317.64
Injection 500 mg
Powder for 4663(E) 25-10-23
670 Vancomycin 1 Vial 470.27
Injection 1000mg
Powder for 1574(E) 31-03-23
671 Vancomycin 1 Vial 251.25
Injection 250 mg
48 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
Notes: -
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the
manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its
formulations. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic
Acid both together corresponding to Sodium Valproate of the stated strength.
50 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
(c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the
manufacturer shall approach NPPA for specific price approval for its formulations.
(d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
(e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price notified vide S.O. & date as specified in column 6 (a) & 6 (b) in the above table (plus Goods and
Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI
@ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013.
(f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
a b
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 51
@ (0.00551%)
0.00551%
≤ 25 एलएफ (≥ 30 पैर्क
आईयू) टे ट्कनि टोटिाइड
≥ 5 एलएफ (≥ 40
आईयू)
158 VsekstksyksekbM xksyh 100 fexzk- 1 xksyh 1925.59 4663 (अ) 25.10.2023
159 fVeksyksy MªksIl 0-25% 1 fefy- 6.44 4663 (अ) 25.10.2023
160 batSD'ku 50 fexzk-@fefy- ¼20 1.55 4663 (अ) 25.10.2023
VªkekMksy 1 fefy-
fefy- iSd½
161 osjkikfey batSD'ku 2-5 fexzk-@fefy- 1 fefy- 1.46 4663 (अ) 25.10.2023
162 fouOykLVhu batSD'ku 1 fexzk-@fefy- 1 fefy- 25.54 1573 (अ) 31.03.2023
163 foVkfeu , dSIlwy 50000 vkbZ;w 1 dSIlwy 0.68 1573 (अ) 31.03.2023
164 izfr iSd ¼10 2.89 1573 (अ) 31.03.2023
okVj QkWj batSD'ku batSD'ku
fefy-½
165 izfr iSd 2.79 1573 (अ) 31.03.2023
okVj QkWj batSD'ku batSD'ku
¼5 fefy-½
166 izfr iSd 57.40 4663 (अ) 25.10.2023
okVj QkWj batSD'ku batSD'ku
¼500 fefy-½
167 izfr iSd 100.74 1573 (अ) 31.03.2023
okVj QkWj batSD'ku batSD'ku
¼1000 fefy-½
168 ftMksoqMkbu dSIlwy 300 fexzk- 1 dSIlwy 2.57 4663 (अ) 25.10.2023
169 tksyfiMse dSIlwy 5 fexzk- 1 dSIlwy 9.15 4663 (अ) 25.10.2023
-
(
0.00551% )
11(3)
(5)
a b िे
0.00551
(5)
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 57
यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की
अवजध में प्रपत्र-II के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की
िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन
नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत
पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।
(4)
(ञ)
(1) u
II I
II III
II IV
Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below
as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
1 5-aminosalicylic Acid Suppository 500 mg 1 Suppository 4663(E) 25.10.2023
21.05
Retention Enema
2 5-aminosalicylic Acid Tablet 400 mg 1 Tablet 9.31 4663(E) 25.10.2023
3 Abacavir (A) + Tablet 60 mg(A) + 1 Tablet 1573(E) 31.03.2023
25.00
Lamivudine (B) 30 mg(B)
4 Acetylsalicylic acid Effervescent/
Dispersible/ Enteric
1 Tablet 0.22 1573(E) 31.03.2023
coated Tablet 100
mg
5 Acetylsalicylic acid Tablet 100 mg 1 Tablet 0.21 1573(E) 31.03.2023
6 Acetylsalicylic acid Tablet 150 mg 1 Tablet 0.50 1573(E) 31.03.2023
7 Acetylsalicylic acid Tablet 350mg 1 Tablet 0.38 1573(E) 31.03.2023
8 Acetylsalicylic acid Tablet 75 mg 1 Tablet 0.38 1573(E) 31.03.2023
9 All-trans Retinoic Acid Capsule 10 mg 1 Capsule 1573(E) 31.03.2023
101.85
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
54 Dinoprostone Tablet 0.5mg 1 Tablet 62.31 4663(E) 25.10.2023
55 Diphtheria antitoxin 10000 IU Each Pack 1631.70 4663(E) 25.10.2023
56 DPT vaccine Per 0.5 ml 17.64 4663(E) 25.10.2023
57 Efavirenz Capsule 600 mg 1 Capsule 78.09 1573(E) 31.03.2023
58 Ethyl Alcohol (Denatured) Solution 70% 1 ml 0.53 4663(E) 25.10.2023
59 Ferrous Salt (A) + Folic Tablet 100mg
Acid (B) elemental iron (A) + 1 Tablet 0.28 1573(E) 31.03.2023
500mcg (B)
60 Fluconazole Oral Liquid
1 ml 3.25 1573(E) 31.03.2023
50mg/5ml
61 Gadobenate Injection 529 mg/ml 1 ml 135.69 4663(E) 25.10.2023
62 Glucose Injection 50% 1 ml 0.61 4663(E) 25.10.2023
63 Glucose Injection 5% 1000ml Glass 79.95 1573(E) 31.03.2023
64 Glucose Injection 5% 1000ml Non- 4663(E) 25.10.2023
64.55
Glass
65 Glucose Injection 5% 100ml Glass 22.45 4663(E) 25.10.2023
66 Glucose Injection 5% 100ml Non- 4663(E) 25.10.2023
20.32
Glass
67 Glucose Injection 5% 250ml Glass 31.01 1573(E) 31.03.2023
68 Glucose Injection 5% 250ml Non- 4663(E) 25.10.2023
28.02
Glass
69 Glucose Injection 5% 500ml Glass 44.02 4663(E) 25.10.2023
70 Glucose Injection 5% 500ml Non- 4663(E) 25.10.2023
37.98
Glass
71 Glucose Injection 10% Each Pack 4663(E) 25.10.2023
32.16
(1000 ml)
72 Glucose Injection 10% Each Pack 1573(E) 31.03.2023
34.97
(500 ml)
73 Glucose (A) + Sodium Injection 5% (A) + 1000ml Glass 1573(E) 31.03.2023
80.48
Chloride (B) 0.9% (B)
74 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non- 1573(E) 31.03.2023
65.03
Chloride (B) 0.9% (B) Glass
75 Glucose (A) + Sodium Injection 5% (A) + 100ml Glass 1573(E) 31.03.2023
22.50
Chloride (B) 0.9% (B)
76 Glucose (A) + Sodium Injection 5% (A) + 100ml Non- 4663(E) 25.10.2023
20.34
Chloride (B) 0.9% (B) Glass
77 Glucose (A) + Sodium Injection 5% (A) + 250ml Glass 4663(E) 25.10.2023
31.14
Chloride (B) 0.9% (B)
78 Glucose (A) + Sodium Injection 5% (A) + 250ml Non- 1573(E) 31.03.2023
28.12
Chloride (B) 0.9% (B) Glass
79 Glucose (A) + Sodium Injection 5% (A) + 500ml Glass 1573(E) 31.03.2023
44.23
Chloride (B) 0.9% (B)
80 Glucose (A) + Sodium Injection 5% (A) + 500ml Non- 1573(E) 31.03.2023
38.21
Chloride (B) 0.9% (B) Glass
81 Glutaraldehyde Solution 2% 1 ml 0.08 4663(E) 25.10.2023
82 Griseofulvin Tablet 125mg 1 Tablet 1.02 1573(E) 31.03.2023
83 Griseofulvin Tablet 375 mg 1 Tablet 5.35 4663(E) 25.10.2023
84 Haemodialysis fluid As license 1 ml 0.04 1573(E) 31.03.2023
85 Human Normal Solution for 1 ml 192.07 1573(E) 31.03.2023
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 61
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
Immunoglobulin infusion 5%
86 Human Normal Solution for
1 ml 260.04 1573(E) 31.03.2023
Immunoglobulin infusion 10%
87 Human Normal Solution for
1 ml 494.52 1573(E) 31.03.2023
Immunoglobulin infusion 16.5%
88 Hydrochlorothiazide Tablet 50 mg 1 Tablet 0.10 1573(E) 31.03.2023
89 Hydrogen peroxide Solution 6% 1 ml 0.04 1573(E) 31.03.2023
90 Hydroxocobalamin Injection 1 mg/ml 1 ML 12.31 1573(E) 31.03.2023
91 Ibuprofen Capsule 400 mg 1 Capsule 1.31 1573(E) 31.03.2023
92 Ibuprofen Capsule 200 mg 1 soft gelatin 1573(E) 31.03.2023
3.33
capsule
93 Imatinib Capsule 400 mg 1 Capsule 318.01 4663(E) 25.10.2023
94 Ipratropium Inhalation
(MDI/DPI) 20 1 Dose 0.76 1573(E) 31.03.2023
mcg/dose
95 Ipratropium Respirator solution
for use in Nebulizer 1 ml 3.15 1573(E) 31.03.2023
250 mcg/ml
96 Ketamine Injection 10 mg/ml 1 ml 13.19 4663(E) 25.10.2023
97 Levonorgestrel Tablet 0.75 mg 1 Tablet 28.65 4663(E) 25.10.2023
98 Levothyroxine Tablet 37.50 mcg 1 Tablet 1.47 4663(E) 25.10.2023
99 Lignocaine (A) + Injection 1% (A) + 1 ml 1573(E) 31.03.2023
Adrenaline (B) 1:200000 (5 0.56
mcg/ml) (B)
100 Lopinavir (A) + Ritonavir Tablet 100 mg(A) + 1 Tablet 4663(E) 25.10.2023
29.28
(B) 25 mg(B)
101 Measles Rubbela Vaccine Each Pack 4663(E) 25.10.2023
110.07
(0.5ml)
102 Measles vaccine Vaccine Each Pack 1573(E) 31.03.2023
63.47
(0.5ml)
103 Methotrexate Injection 50 mg/ml 1 ml 49.86 1573(E) 31.03.2023
104 Methylrosanilinium Paint 1% 1 ml 1573(E) 31.03.2023
0.10
chloride (Gentian Violet)
105 Methylthioninium Injection 10mg/ml 1 ML 1573(E) 31.03.2023
27.13
chloride (Methylene blue)
106 Midazolam Tablet 7.5mg 1 Tablet 27.94 1573(E) 31.03.2023
107 Morphine SR Tablet 30 mg 1 Tablet 6.78 1573(E) 31.03.2023
108 Morphine Tablet 10 mg 1 Tablet 6.63 4663(E) 25.10.2023
109 N-acetylcysteine Sachet 200mg 1 gm 11.20 1573(E) 31.03.2023
110 Nevirapine Oral Liquid 50 1 ml 1573(E) 31.03.2023
1.04
mg/5ml
111 Omeprazole Tablet 10 mg 1 Tablet 5.52 4663(E) 25.10.2023
112 Oral poliomyelitis vaccine 1 ml 127.67 1573(E) 31.03.2023
113 Oral Rehydration Salts As Licensed 1 gm 1.11 1573(E) 31.03.2023
114 Oxaliplatin Injection 100mg(as
Each Pack 5563.91 4663(E) 25.10.2023
licensed)
115 Para-aminosalicylic acid Granules (As
1 gm 3.54 1573(E) 31.03.2023
licensed)
116 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023
3.82
( 0.5 ml)
62 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
117 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023
5.22
(1 ml)
118 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023
10.84
(3 ml)
119 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023
13.65
(4 ml)
120 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023
16.46
(5 ml)
121 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023
22.07
(7 ml)
122 Penicillamine Capsule 250 mg 1 Capsule 18.50 1573(E) 31.03.2023
123 Phenylephrine Drop 10% 1 ml 10.06 4663(E) 25.10.2023
124 Phenylephrine Drops 5% 1 ml 4.64 1573(E) 31.03.2023
125 Phenytoin ERCapsule 300 mg 1 Capsule 4.74 1573(E) 31.03.2023
126 Phenytoin injection 25 mg/ml 1 ml 3.13 4663(E) 25.10.2023
127 Pilocarpine Drops 4% 1 ml 14.54 1573(E) 31.03.2023
128 Potassium permanganate Crystals for topical 1 gm 4663(E) 25.10.2023
0.55
solution
129 Povidone iodine Scrub 7.5% 1 ml 2.00 4663(E) 25.10.2023
130 Povidone iodine Ointment 10% 1 gm 6.48 1573(E) 31.03.2023
131 Praziquantel Tablet 600 mg 1 tablet 43.25 4663(E) 25.10.2023
132 Prednisolone Injection 20 mg/2ml 1 ml 4.46 1573(E) 31.03.2023
133 Pyrazinamide Oral Liquid 250 1 ml 1573(E) 31.03.2023
0.76
mg/5ml
134 Rifampicin Tablet 150 mg 1 Tablet 2.01 4663(E) 25.10.2023
135 Rifampicin Tablet 300 mg 1 Tablet 3.66 4663(E) 25.10.2023
136 Ringer Lactate Injection 1000ml Each Pack 99.32 4663(E) 25.10.2023
137 Ringer Lactate Injection 100ml Each Pack 26.00 1573(E) 31.03.2023
138 Ringer Lactate Injection 250ml Each Pack 44.33 1573(E) 31.03.2023
139 Ringer Lactate Injection 500ml Each Pack 56.50 4663(E) 25.10.2023
140 Ritonavir Capsule 100 mg 1 Capsule 35.14 4663(E) 25.10.2023
141 Salbutamol Capsule 4 mg 1 Capsule 0.74 1573(E) 31.03.2023
142 Silver Sulphadiazine Cream 1% 1 gm 0.63 4663(E) 25.10.2023
143 Sodium Chloride Injection 0.9% 1000ml Glass 73.88 4663(E) 25.10.2023
144 Sodium Chloride Injection 0.9% 1000ml Non- 4663(E) 25.10.2023
58.27
Glass
145 Sodium Chloride Injection 0.9% 100ml Glass 21.84 1573(E) 31.03.2023
146 Sodium Chloride Injection 0.9% 100ml Non- 4663(E) 25.10.2023
19.68
Glass
147 Sodium Chloride Injection 0.9% 250ml Glass 29.47 4663(E) 25.10.2023
148 Sodium Chloride Injection 0.9% 250ml Non- 4663(E) 25.10.2023
26.45
Glass
149 Sodium Chloride Injection 0.9% 500ml Glass 40.97 4663(E) 25.10.2023
150 Sodium Chloride Injection 0.9% 500ml Non- 4663(E) 25.10.2023
34.87
Glass
151 Sodium nitrite Injection 30 mg/ml 1 ml 32.35 4663(E) 25.10.2023
152 Sodium Nitroprusside Injection 10 mg/ml 1 ml 32.15 4663(E) 25.10.2023
153 Streptokinase Injection 7,50,000 Each Pack 4663(E) 25.10.2023
1567.42
IU
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 63
Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date
No. Strength 1.4.2024 with WPI
@ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5) 6(a) 6(b)
154 Surfactant Suspension for
Per mg of
intratracheal
Phospholipids 83.27 1573(E) 31.03.2023
instillation (As
in the pack
liensed)
155 TD Vaccine Each dose of 0.5ml
contains: Diphtheria
Toxoid ≤5Lf (≥ Each 0.5ml
23.33 1573(E) 31.03.2023
2IU) Tetanus Pack
Toxoid ≥ 5Lf (≥
40IU)
156 TD Vaccine Each dose of 0.5ml
contains: Diphtheria
Toxoid ≤5Lf (≥
Each 5ml Pack 219.25 1573(E) 31.03.2023
2IU) Tetanus
Toxoid ≥ 5Lf (≥
40IU)
157 TD Vaccine Each dose of 0.5ml
contains: Diphtheria
Toxoid ≤25Lf (≥ Each 0.5ml
20.00 1573(E) 31.03.2023
30IU) Tetanus Pack
Toxoid ≥ 5Lf (≥
40IU)
158 Temozolomide Tablet 100 mg 1 Tablet 1925.59 4663(E) 25.10.2023
159 Timolol Drops 0.25% 1 ml 6.44 4663(E) 25.10.2023
160 Tramadol Injection 50 mg/ml
1 ml 1.55 4663(E) 25.10.2023
(20 ml Pack)
161 Verapamil Injection 2.5 mg/ml 1 ml 1.46 4663(E) 25.10.2023
162 Vinblastine Injection 1mg/ml 1 ml 25.54 1573(E) 31.03.2023
163 Vitamin A Capsule 50000 IU 1 Capsule 0.68 1573(E) 31.03.2023
164 Water for Injection Injection Each Pack (10
2.89 1573(E) 31.03.2023
ml)
165 Water for Injection Injection Each Pack (5
2.79 1573(E) 31.03.2023
ml)
166 Water for Injection Injection Per 500 ml
57.40 4663(E) 25.10.2023
Pack
167 Water for Injection Injection Per 1000 ml
100.74 1573(E) 31.03.2023
Pack
168 Zidovudine Capsule 300 mg 1 Capsule 2.57 4663(E) 25.10.2023
169 Zolpidem Capsule 5 mg 1 Capsule 9.15 4663(E) 25.10.2023
Notes: -
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale
Price Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured the
manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its
formulations.
(c) In respect of any other scheduled formulation for which ceiling price is not mentioned above,
themanufacturer shall approach NPPA for specific price approval for its formulations.
(d) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of
scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as
applicable) so fixed and notified by the Government, shall revise the prices of all such formulations
downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and
Services Taxes as applicable, if any.
64 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
(e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus
Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on
the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013.
(f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to
the Government on the ceiling price mentioned in column (5) of the above said table.
(g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer
in accordance with the ceiling price specified in column (5) of the above table as per provisions contained
in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in
Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and
submit a copy to State Drug Controller and dealers.
(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries
on business in a manner so as to be easily accessible to any person wishing to consult the same.
(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II
of the DPCO, 2013.
(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
a
b
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 65
@ 0.00551% बढाकर
0.00551%
01.04.2024 से प्रभावी) ( )
(5)
0.00551%
घ (5)
ङ यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध
में प्रपत्र-II के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस
उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना
माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत
अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।
च
(4)
66 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
1 u
II I
झ
II III
II IV
ञ
(ट)
, नवम्बर
4, 6, 10, 11, 14, 16, 17 18
a b
एनएलईए
म, आदे श र्के
0.00551%
र्के अनि
ु ाि िंशोधित
अंतगित अधिर्कतम र्कीमत
(1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b)
ओरल
मलमक्वड 31015/21/202
सेफ्यूरोमक्स 125 3-
1. ि मिलीग्राि / 1 मि.ली. 5.31 5.31 1574(अ) 31-03-23
5.28
5 मि.ली. 08.02.2024
(पी)
गोली 5
मिलीग्राि 31015/12/202
3-
2. िोंटेलक
िं ास्ट (चबाने 1 गोली 12.01 12.01 4663(अ) 25-10-23
योग्य समहत 11.72
19.02.2024
गोली)
(6)
के
िे . . को
या बराबर
0.00551
यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध
में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और
इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया
िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत
अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।
(4)
(1) u
II I
II III
II
IV
ORDER
New Delhi, the 26th March, 2024
S.O. 1550(E).—In implementation of directions of review orders issued by the Department of
Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order(s) specified in column (8) of
the table below and in exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs
(Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical
Pricing Authority) S.O. Number and date specified in column no. 9(a) & 9(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (6) and further
revised the prices w. e. f. 01.04.2024 specified in column (7) of the table herein below as ceiling prices exclusive of
Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding
entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the
corresponding entries in columns (3) and (4) thereof:
TABLE
Ceiling
Revised
Ceiling price
ceiling
Price (wef
price as Review Order
Sl. Dosage form & under 1.4.2024 Existing SO
Medicines Unit per number and
No. Strength NLEM, with WPI number and date
review date
2022 @
order
(Rs.) 0.00551%)
(in Rs.)
(in Rs.)
(1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b)
31015/21/2023
Oral liquid 1574
1. Cefuroxime 1 ML 5.31 5.31 -Pricing dated 31-03-23
125mg/5mL(p) 5.28 (E)
08.02.2024
Tablet 5 mg 31015/12/2023
1 4663
2. Montelukast (including 12.01 12.01 -Pricing dated 25-10-23
Tablet 11.72 (E)
chewable Tablet s) 19.02.2024
31015/13/2023
Mycophenol 1 4663
3. Tablet 500mg 74.59 74.59 -Pricing dated 25-10-23
ate mofetil Tablet 73.88 (E)
22.02.2024
Notes: -
(a) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) as fixed and
notified by the Government as specified in column (6) of the above table, shall revise the prices of all such
formulations downward not exceeding the ceiling price specified in column (6) plus Goods and Services
Taxes as applicable, if any.
(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price as specified in column (6) in the above table (plus Goods and Services Taxes as applicable, if
any) shall continue to maintain the existing MRP in accordance with para 13(2) of DPCO,2013 till
31.03.2024.
(c) The ceiling prices as specified in column (7) of the table are applicable with effect from 01.04.2024 (ceiling
prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). All the
existing manufacturers of above-mentioned scheduled formulations having MRP lower or equal than the
ceiling price as specified in column (6), as on 31.03.2024, in the above table (plus Goods and Services Taxes
as applicable, if any) may revise the MRP on the basis of WPI @ 0.00551% for year 2023 over 2022 in
accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (6) and/or (7) of the above said table.
(e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 71
(f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (6) and/or (7) applicable of the above table as per
provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall
issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA
through IPDMS and submit a copy to State Drug Controller and dealers.
(g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(i) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
का. आ. 1551(अ).—
, ,
. . , . . , . . ,
. . , . . . .
@ 0.00551%
, ,
0.00551%
I 01.04.2024 िे
प्रभावी
10509.79
38267.18
72 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
13(2)
@ 0.00551%
(4)
ORDER
New Delhi, the 26th March, 2024
S.O. 1551(E).—In continuation of the notifications issued by National Pharmaceutical Pricing Authority,
Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018, S.O.
1464(E) dated 02.04.2018, S.O. 1488(E) dated 29.03.2019, SO. 1217(E) dated 25.03.2020, S.O. 1334(E) dated
25.03.2021, 1502(E) dated 30.03.2022, 5249(E) dated 11.11.2022, 1572(E) dated 31.03.2023 and 4663(E) dated
25.10.2023 regarding the fixation of ceiling price of the Coronary Stents as specified in column no. (2) mentioned in
the table below; after considering the Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022, it
has been decided to revise the ceiling prices of Coronary Stents as mentioned in column no. (4) in the table below,
exclusive of Goods and Services Tax as applicable,and unit specified in column (3) with effect from 01.04.2024, as
under:
TABLE
Sl. No. Coronary Stents Unit Ceiling price
(Sl. No. 28 in Schedule-I of the DPCO, 2013) (in Number) (wef 1.4.2024
with WPI @0.00551%)
(in Rs.)
(1) (2) (3) (4)
1 Bare Metal Stents 1 10509.79
Drug Eluting Stents (DES) including metallic DES and
2 Bioresorbable Vascular Scaffold (BVS)/ Biodegradable 1 38267.18
Stents
Notes: -
(a) All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price
specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may
revise the existing MRP of Coronary Stent, on the basis of WPI @ 0.00551% for the year 2023 over
2022 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 73
(b) The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have
paid actually or if it is payable to the Government on the ceiling price mentioned in column (4) of the
aforesaid table.
(c) As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer/importers, on a conspicuous part of the premises
where he carries on business in a manner so as to be easily accessible to any person wishing to consult
the same.
(d) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable
to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955
@ 0.00551% बढाकर
@ 0.00551%
0.00551%
र्के 5, 6, 7 औि 8 मे दशािई गई र्कीमते र्केवल मैससच
पुजनस्ट्का हेल्थके यर प्रा०जलजमटेड ( र्के 19) पर लागू होंगी.
र्के 1, 2, 3, 4, 5, 7 औि 8 मे दशािई गई र्कीमते र्केवल
मैससच जहलस हेल्थके यर ( र्के 21) पर लागू होंगी.
र्के 2, 4, 5 औि 7 मे दशािई गई र्कीमते र्केवल मैससच प्यूटो
लाइफ साइं सेि प्राइवेट जलजमटेड ( र्के 23) पर लागू होंगी.
र्के 2, 4, 5, 6 औि 7 मे दशािई गई र्कीमते र्केवल मैससच
सजर्न पैरेंटेरल प्रा .जलजमटेड ( र्के 24) पर लागू होंगी.
र्के 1, 2, 3, 4, 5, 7 औि 8 मे दशािई गई र्कीमते र्केवल
मैििि बायोमिनजी लाइफर्केयि प्राइवेट मलममटे ड ( र्के 25) पि
लागू होंगी.
र्के 2, 4, 5 औि 7 मे दशािई गई र्कीमते र्केवल मैििि
प्रोममया िेिेप्यूट्रटटि प्राइवेट मलममटे ड ( र्के 26) पि लागू होंगी.
(5)
dk- vk- 1571¼v½ fnukad 31.03.2023, dk-vk- 4663¼v½ fnukad 25.10.2023, dk-
vk- 4887¼v½ fnukad 10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02.02.2024
0.00551%
ञ (5)
ठ यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की
अवजध में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की
िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन
नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की जतजथ से उस पर ब्याि सजहत
पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा।
76 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
(4)
(1) u
II I
(त)
II III
II IV
थ
( द)
ORDER
New Delhi, the 26th March, 2024
S.O. 1552(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22 nd
March, 2016, S.O. 5249(E) dated 11 th November, 2022 issued by the Government of India in the Ministry of
Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals
and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1571(E) dated 31.03.2023, 4663(E) dated
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 77
25.10.2023, 4887(E) dated 10.11.2023 and 424(E) dated 02.02.2024 in so far as they relate to formulation packs
mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and
pack-sizes, except in respect of things done or omitted to be done before such supersession, the National
Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as
specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax
applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the
said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in
columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase
Sl. No. Medicines Dosage form and Unit Ceiling price
Strength (w.e.f.01.04.2024 with WPI
@ 0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Glucose Injection 5% 1000ml NonGlass with special
95.11
features
2 Glucose Injection 5% 500ml Non Glass with special
82.27
features
3 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non Glass with special
99.94
Chloride (B) 0.9% (B) features
4 Glucose (A) + Sodium Injection 5% (A) + 500ml Non Glass with special
85.52
Chloride (B) 0.9% (B) features
5 Sodium Chloride Injection 0.9% 100ml Non Glass with special
42.06
features
6 Sodium Chloride Injection 0.9% 250ml Non Glass with special
62.10
features
7 Sodium Chloride Injection 0.9% 500ml Non Glass with special
87.94
features
8 Sodium Chloride Injection 0.9% 1000ml Non Glass with special
98.51
features
TABLE B
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s B.Braun Medical (I) Pvt Ltd. Ecoflac Plus bottle with Eurohead
2 M/s Amanta Healthcare Ltd. Steriport bottle
3 M/s Aculife Healthcare Pvt Ltd. Aculife bottle with Eurohead
4 M/s Albert David Limited Albert David bottle with Eurohead
5 M/s Denis Chem Limited Aquapulse with Eurohead
6 M/s Claris Life Sciences Limited Claris bottle with Eurohead
7 M/s Fresenius Kabi India Pvt Limited Freeflex bags
8 M/s Otsuka Pharmaceutical India Private Ltd. Unibag
(previously known as Claris Otsuka Private Limited)
9 M/s Aishwarya Lifesciences LifusionEurohead bottle
10 M/s Baxter (India) Pvt. Ltd. Viaflex bags
11 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
(previously known as Claris Otsuka Private Limited)
12 M/s Fresenius Kabi India Pvt Limited Eurohead bottle
13 M/s Axa Parenterals Ltd Steri Drip bottle with Eurohead
14 M/s Shree Krishna Keshav Laboratories Ltd Easyport bottle with Eurohead
15 M/s Rusoma Laboratories Pvt. Ltd. Puradrip
16 M/s R. K. Laboratories Pvt. Ltd. Eurohead bottle
78 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
23 M/s Puerto life Sciences Private Limited [Note (d) Euro head bottle
below]
24 M/s Sachin Parenteral Pvt. Ltd. [Note (e) below] “SAFE PORT”
25 M/s Biosynergy Lifecare Pvt. Ltd. [Note (f) below] “BIOPORT”
26. M/s Promea Therapeutics Pvt. Ltd. [Note (g) below] LDPE Bottle/ Non-Glass container with special features
Euro head Cap
Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In case of M/s Puniska Healthcare Pvt. Ltd.mentioned in Sl. No. 19 of Table B, only the prices of the
formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable.
(c) In case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified
in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(d) In case of M/s Puerto life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable.
(e) In case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations
specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable.
(f) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 25 of Table B, only the prices of the
formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(g) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 26 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable.
(h) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations
at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the
Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified
in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(i) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified
vide S.O. No. 1571(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. No. 4887(E) dated 10.11.2023
and S.O. No. 424(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the
existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance
with paragraph 16(2) of DPCO, 2013.
(j) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(k) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA
for separate ceiling price approval with details and demonstrate, that such pack alongwith documentation and
demonstration.
(l) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price
(MRP), alongwith interest thereon from the date of overcharging.
(m) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 79
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to
State Drug Controller and dealers.
(n) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(o) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(p) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through
IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish
information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in
Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(q) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit
the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order,
2013 read with Essential Commodities Act, 1955.
(r) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this
notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
@ 0.00551% बढा
@ 0.00551%
(1) (2) 3
1 मैििि अेबटि डेववड मल. यिू ोहे ड
2 मैििि एटयल
ू ाइफ हे ेिर्केयि प्रा. मलममटे ड यिू ोहे ड
3 मैििि बी। ब्रौन मेडडर्कल प्रा (इंडडया). मलममटे ड यिू ोहे ड र्के िाि इर्कोफ्लैर्क प्लि बोतल
4 मैििि फ्रेिेननयि र्काबी इंडडया प्रा. मलममटे ड फ़्रीफ़्लेटि बैग
5 मैििि ओस्तर्क
ु ा फामािस्यट्रू टर्केि इंडडया प्रा. यिू ोहे ड बोतल
मलममटे ड
9 मैििि अटिा पैिेंटेि मलममटे ड यिू ोहे ड र्के िाि स्टे रिडडप
11 मैििि आि. र्के. लेबोिे टिीज प्रा० मलममटे ड यिू ोहे ड बोतल
12 मैििि रियलर्केड लाईफिाइंि प्रा० मलममटे ड ववशेष िवु विाओं र्के िाि गैि-ललाि
13. मैििि अबैरिि हे ेिर्केयि प्रा० मलममटे ड (नीर्े ववशेष िवु विाओं र्के िाि गैि-ललाि
14. मैििि ट्रहलि हे ेिर्केयि (नीर्े ववशेष िवु विाओं र्के िाि गैि-ललाि
15. मैििि रूिोमा लेबोिे टिीज प्रा०मलममटे ड (नीर्े यिू ोहे ड बोटल ड्यडू ड्रप र्के िाि
16. मैससच प्यूटो लाइफ साइं सेि प्राइवेट जलजमटेड (नीर्े यिू ोहे ड बोतल
17. मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड (नीर्े "िेफ पोटि "
0.00551%
र्के 2, 3 औि 4 मे दशािई गई र्कीमते र्केवल मैससच मैििि अबैरिि
हे ेिर्केयि प्रा० मलममटे ड ( र्के 13) औि मैििि रूिोमा लेबोिे टिीज
प्रा०मलममटे ड ( र्के 15) पि लागू होंगी .
र्के औि 4 मे दशािई गई र्कीमते र्केवल मैििि ट्रहलि हे ेिर्केयि
( र्के 14) पर लागू होंगी.
र्के 3 मे दशािई गई र्कीमते र्केवल मैससच प्यूटो लाइफ साइंसेि
प्राइवेट जलजमटेड ( र्के 16), मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड (
र्के 17) औि मैससस प्रोसमया थेरेप्यूसटक्स प्राइवेट सलसमटे ड ( र्के 19)
पि लागू होंगी .
र्के औि 4 मे दशािई गई र्कीमते र्केवल मैससस बायोससनर्जी
लाइफकेयर प्राइवेट सलसमटे ड ( र्के 18) पि लागू होंगी.
(5)
dk-
vk- 1570¼v½ fnukad 31 ekpZ] 2023, dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½ fnukad
10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024
0.00551%
(5)
(ञ) यदि संिोधन दकया िाता है तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर
की अवजध में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को
अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम
खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेने की
जतजथ से उस पर ब्याि सजहत पूव-च संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की
राजि िमा करने के जलए उत्तरिायी होगा।
V
82 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
(4)
(1) u
II I
ढ
II III
II IV
ORDER
New Delhi, the 26th March, 2024
S.O. 1553(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 of the Drugs
(Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30 th May, 2013, S.O. 1192(E) dated 22nd March, 2016,
S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and
Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers
(National Pharmaceutical Pricing Authority) S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O.
4888(E) dated 10.11.2023 and S.O. 425(E) dated 02.02.2024 in so far as it relates to formulation packs mentioned in
the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes,
except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing
Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specified in column (5) of the
Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of
the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form
and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Unit Ceiling price
No. Strength (w.e.f.01.04.2024 with WPI
@ 0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Ringer lactate Injection100 ml Each 100 ml pack having special
29.90
features
2 Ringer lactate Injection 250 ml Each 250 ml pack having special
50.99
features
[भाग II—खण्ड 3(ii)] भारत का रािपत्र : असाधारण 83
3 Ringer lactate Injection 500 ml Each 500 ml pack having special
64.96
features
4 Ringer lactate Injection 1000 ml Each 1000 ml pack having special
114.21
features
TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
3 M/s B. Braun Medical (India) Pvt. Ltd. Ecoflac Plus bottle with Eurohead
13 M/s Abaris Healthcare Pvt. Ltd (Note (b) below) Non-glass with special features
14 M/s Higgs Healthcare (Note (c) below) Non-glass with special features
16 M/s Puerto life Sciences Private Limited (Note (d) below) Eurohead bottle
17 M/s Sachin Parenteral Pvt. Ltd. (Note (d) below) “SAFE PORT”
Notes:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) In case of M/s Abaris Healthcare Pvt. Ltd. (Sl. No. 13 of Table B) & M/s Rusoma Laboratories Pvt. Ltd. (Sl.
No. 15 of Table B), only the prices of the formulations specified in Sl. No. 2, 3 & 4 of Table A are applicable.
(c) In case of M/s Higgs Healthcare mentioned in Sl. No. 14 of Table B, only the prices of the formulations
specified in Sl. No. 3 & 4 of Table A are applicable.
(d) In case of M/s Puerto life Sciences Private Limited (Sl. No. 16 of Table B), M/s Sachin Parenteral Pvt. Ltd.
(Sl. No. 17 of Table B) & M/s Promea Therapeutics Pvt. Ltd. (Sl. No. 19 of Table B), only the prices of the
formulations specified in Sl. No. 3 of Table A are applicable.
(e) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 18 of Table B, only the prices of the
formulations specified in Sl. No. 3 & 4 of Table A are applicable
(f) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
84 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(g) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. 4888(E) dated 10.11.2023
and S.O. 425(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing
M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over the year 2022 in accordance
with paragraph 16(2) of DPCO, 2013.
(h) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(i) Any other manufacturer claiming separate ceiling price for ringer lactate injection in pack having special
features shall apply to NPPA for separate ceiling price approval.
(j) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(k) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy
to State Drug Controller and dealers.
(l) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(m) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(n) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect
of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(o) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control)
Order, 2013 read with Essential Commodities Act, 1955.
(p) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
@ 0.00551%
(@ 0.00551%
(3)
मैससस गुपिक बाय़ोसाइसं ेज पिपमटेड टैज़ोपिक इजं ेक्शन (डीसीबी)
0.00551%
15.09.2023
0.00551%
86 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
u
II I
ञ
II III
II IV
ORDER
New Delhi, the 26th March, 2024
S.O. 1554(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 4077(E) dated 15.09.2023 in so far as it relate to formulation packs mentioned in the Table A
below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in
respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority,
hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A
herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 87
scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and
strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Strength Unit Ceiling price (wef
No. 01.04.2024 with WPI
@ 0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Piperacillin (A) + Powder for Per Dual chamber bag with
special feature
Tazobactam (B) Injection 2 g (A) + 220.27
250 mg(B)
2 Piperacillin (A) + Powder for Per Dual chamber bag with
special feature
Tazobactam (B) Injection 4 g (A) + 459.31
500 mg(B)
TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s Gufic Biosciences Limited Tazofic Injection (DCB)
Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. No. 4077(E) dated 15.09.2023 (plus Goods and Services Tax as applicable, if any), may
revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in
accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Piperacillin (A) + Tazobactam (B) Injection (i)
Powder for injection 2g (A) + 250gm (B) (ii) 4g (A) + 500gm (B) Per Dual chamber bag having special
features shall apply to NPPA for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
88 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
0.00551%
(@ 0.00551%
4. र्ेससासवचिपैरेंटेरलप्रा.वलवर्टेड "सेफपोटा"
0.00551%
0.00551%
u
II I
90 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
ञ
II III
II IV
ORDER
New Delhi, the 26th March, 2024
S.O. 1555(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 1576(E) dated 31.03.2023, 1584(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated
10.11.2023 and 426(E) dated 02.02.2024 in so far as it relate to formulation packs mentioned in the Table A below,
manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of
things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby
revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein
below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled
formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength
and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Strength Unit Ceiling price (wef
No. 01.04.2024 with WPI @
0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Metronidazole Injection (0.5%w/v) /500mg/100ml Per ml
in 100ml pack for packages in non- 0.25
glass with special features
TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle
3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle
4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT”
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 91
5 M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT”
6 M/s Promea Therapeutics Pvt. Ltd. PROCAP-MT
Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. No. 1576(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated 10.11.2023 and
426(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P.
of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with
paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Metronidazole Injection (0.5%w/v) /500mg/
100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special
features shall apply to NPPA for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
92 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
0.00551%
(@ 0.00551%
4. र्ेससासवचिपैरेंटेरलप्रा.वलवर्टेड "सेफपोटा"
@0.00551%
31.03.2023, 31.03.2023
10.11.2023
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 93
0.00551%
u II
I
(ञ)
II III
II IV
ORDER
New Delhi, the 26th March, 2024
S.O. 1556(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. No. 1575(E) dated 31.03.2023, S. O. No. 1583(E) dated 31.03.2023 and S.O. No. 4890(E) dated
94 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
10.11.2023 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the
manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted
to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on
Wholesale price index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price
exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the
corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified
respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024
with WPI @ 0.00551%) (in
Rs.)
(1) (2) (3) (4) (5)
1 Mannitol Injection 20% in 100 ml pack for packages in Per ml 0.40
non-glass with special features
TABLE ‘B’
Sl. No. Name of Manufacturer Product /Brand Name
(1) (2) (3)
1 M/s. Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
2 M/s. Denis Chem Lab Ltd. Eurohead Propylene Bottle
3 M/s. Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle
4 M/s. Sachin Parenteral Pvt. Ltd. “SAFE PORT”
5 M/s. Biosynergy Lifecare Pvt. Ltd. “BIOPORT”
Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O. No. 1575(E) dated 31.03.2023, S.O. No. 1587(E) dated 31.03.2023 and S.O. No. 4890(E)
dated 10.11.2023 read with corrigendum (plus Goods and Services Tax as applicable, if any), may revise the
existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in
accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Mannitol Injection 20% in 100 ml pack for
packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA
for separate ceiling price approval.
(f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 95
(h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
0.00551%
(@ 0.00551%
4. र्ेससासवचिपैरेंटेरलप्रा.वलवर्टेड "सेफपोटा"
0.00551%
31.03.2023, 10.11.2023
02.02.2024
0.00551%
(ञ)
u II
I
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 97
II III
II IV
(ड) bl vkns’k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh
vf/kdre dher fu;r gksus ds ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns’k] ;fn dksbZ gks] tks bl
vkns’k ls iwoZ tkjh gq, gSa] Lor% gh vf/kØe.k gks tk;sx
a sA
[dka- la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II]
युविकापंिार, सहायकविदेशक
ORDER
New Delhi, the 26th March, 2024
S.O. 1557(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession
of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) S.O. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated 02.02.2024 in so far
as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in
Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such
supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price
index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of
Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding
entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in
the corresponding entries in columns (3) and (4) thereof:
Table A
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase.
Sl. Medicines Dosage form and Strength Unit Ceiling price (wef
No 01.04.2024 with WPI @
0.00551%) (in Rs.)
(1) (2) (3) (4) (5)
1 Dextrose Injection (25% w/v) in 100 ml pack for packages Per ml 0.24
(Glucose) in non-glass with special features
TABLE ‘B’
Sl. Name of Manufacturer Product /Brand Name
No.
(1) (2) (3)
1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle
2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle
3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle
4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT”
5. M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT”
6. M/s Promea Therapeutics Pvt. Ltd. PROCAP-D25
98 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
Note:
(a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.00551% for the year 2023 over 2022).
(b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled
formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price
notified vide S.O.No. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated
02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their
formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2)
of DPCO, 2013.
(d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100
ml pack for packages in non-glass container in plastic bottle with euro head having special features shall
apply to NPPA for separate ceiling price approval.
(f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach
NPPA for specific price approval for its formulation.
(g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of
the DPCO, 2013.
(k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table
in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date
of notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 99
तावलका
ORDER
New Delhi, the 26th March, 2024
S.O. 1558(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below
as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the
corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Abbott Healthcare
Sitagliptin Phosphate
Hydrochloride Pvt. Ltd.
Monohydrate IP eq. to
(Sustained Released)
1 Sitagliptin 100mg 1 Tablet 14.00
Tablet
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
500mg (Sustained Release Form)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Abbott Healthcare
Sitagliptin Phosphate
Hydrochloride Pvt. Ltd.
Monohydrate IP eq. to
(Sustained Released)
Sitagliptin 100mg
2 Tablet 1 Tablet 15.32
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
1000mg (Sustained Release
Form)
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 109
Sl. Name of the Strength Unit Manufacturer & Retail
No. Formulation / Marketing Company Price
Brand Name (Rs.)
(1) (2) (3) (4) (5) (6)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Mankind Pharma
Sitagliptin Phosphate
Hydrochloride Ltd.
Monohydrate IP eq. to
(Sustained Released)
Sitagliptin 100mg
3 Tablet 1 Tablet 15.32
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
1000mg (Sustained Release
Form)
Sitagliptin, Each film coated Bilayered M/s Akums Drugs &
Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. /
Metformin M/s Mankind Pharma
Sitagliptin Phosphate
Hydrochloride Ltd.
Monohydrate IP eq. to
(Sustained Released)
4 Sitagliptin 100mg 1 Tablet 14.00
Tablet
Pioglitazone Hydrochloride IP
eq. to Pioglitazone 15 mg
Metformin Hydrochloride IP
500mg (Sustained Release Form)
Metoprolol Each film coated bilayered tablet M/s Ajanta Pharma
Succinate Extended contains: Limited / M/s Sun
Release, Amlodipine Pharma Laboratories
Metoprolol Succinate IP
and Telmisartan Limited
47.50mg eq. to Metoprolol
Tablet
5 Tartrate 50mg (As Extended 1 Tablet 14.60
release)
Amlodipine Besilate IP eq. to
Amlodipine 5mg
Telmisartan IP 40mg
Linagliptin & Each film coated bilayered tablet M/s Mascot Health
Metformin contains: Series Pvt. Ltd. / M/s
6 Hydrochloride 1 Tablet Lupin Limited 13.03
Linagliptin IP 5mgMetformin
(Extended Release)
Hydrochloride IP 500mg (As
Tablets
Extended release)
Vitamin D3 Each 5 ml syrup contains: M/s Ravenbhel
(Cholecalciferol) Healthcare Pvt. Ltd. /
7 Cholecalciferol IP 60000IU 1 ml 12.53
Oral Solution M/s Emcure
Pharmaceuticals Limited
Cholecalciferol Each 5ml contains: M/s Ravenbhel
(Vitamin D3) Oral Healthcare Pvt. Ltd. /
8 Cholecalciferol IP (In nano 1 ml 13.60
Solution 60000IU M/s Intas
Droplet form) 60000IU
Pharmaceuticals Ltd.
Linagliptin + Each film coated tablet contains: M/s Morepen
Metformin Laboratories Limited
Linagliptin 2.5mg
9 Hydrochloride 1 Tablet 8.97
Tablet Metformin Hydrochloride IP
500mg
Note:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
रे र्ोवग्लफ़्लोवजिएटाबोिेट, रे र्ोवग्लफ़्लोवजिएटाबोिेट100
वर्.ग्रा. र्ैससाग्लेिर्ाका
1. विल्डावग्लवप्टिऔर 1 गोली 8.76
र्ेटफॉर्र्ािहाइड्रोक्लोराइड विल्डावग्लवप्टि50वर्.ग्रा. फार्ाास्यूटटकल्सवलवर्टेड
गोवलयााँ
र्ेटफोर्र्ाि हाइड्रोक्लोराइड आईपी
500वर्लीग्रार्
कम्पोजीसि:
रे र्ोवग्लफ़्लोवजिएटाबोिेट100
एटाबोिेट, विल्डावग्लवप्टि वर्.ग्रा. र्ैससाग्लेिर्ाका
2. औरर्ेटफॉर्र्ाि 1 गोली 9.06
विल्डावग्लवप्टि50वर्.ग्रा. फार्ाास्यूटटकल्सवलवर्टेड
हाइड्रोक्लोराइडगोवलयााँ
र्ेटफोर्र्ाि हाइड्रोक्लोराइड आईपी
1000वर्लीग्रार्
प्रत्येकिाईलर्ें:
र्ेससाबीडीआर
सेफ्टावजडाइर्और
सेफ्टावजडाइर्(सेफ्टावजडाइर् फार्ाास्यूटटकल्सइं टरिेशिल
एविबैक्टर्पाउडरफोर
3. पेंटाहाइड्रेटके रूपर्ें)आईपी2ग्रार् 1 िाईल प्राइिेटवलवर्टेड 1696.43
कोंसंरेटफोरशोलूसिफोर
वलवर्टेड/र्ैससािैटकोफार्ाा
इं फ्यूजि एविबैक्टर्सोवडयर्एविबैक्टर्0.5
वलवर्टेड
ग्रार्के बराबर
I
120 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
ORDER
New Delhi, the 26th March, 2024
S.O. 1559E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below
as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the
corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
Sl. Name of the Strength Unit Manufacturer & Retail Price
No. Scheduled Marketing Company (Rs.)
Formulation / Brand
Name
(1) (2) (3) (4) (5) (6)
1. Composition:
Remogliflozin Remogliflozin Etabonate
Etabonate, 100mg M/s Glenmark
Vildagliptin & 1 Tablet Pharmaceuticals 8.76
Metformin Vildagliptin 50mg Limited
Hydrochloride tablets Metformin Hydrochloride
IP 500mg tablets
2. Composition:
Remogliflozin
Remogliflozin Etabonate
Etabonate, M/s Glenmark
100mg
Vildagliptin & 1 Tablet Pharmaceuticals 9.06
Metformin Vildagliptin 50 mg Limited
Hydrochloride tablets Metformin Hydrochloride
IP 1000 mg tablets
3. Each vial contains:
M/s BDR
Ceftazidime and Ceftazidime (As
Pharmaceuticals
Avibactam powder Ceftazidime pentahydrate)
1Vial Internation Pvt. Ltd. / 1696.43
for concentrate for IP 2gram
M/s Natco Pharma
solution for infusion
Avibactam Sodium eq. to Limited
Avibactam 0.5gm
Note:
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
[भाग II—खण्ड 3(ii)] भारतकाराजपत्र:असाधारण 121
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]
YUVIKA PANWAR, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054. MANOJ KUMAR
Digitally signed by
MANOJ KUMAR VERMA
VERMA Date: 2024.03.30
13:53:34 +05'30'